Regeneron Pharmaceuticals Inc REGN top line results from a mid-stage study of Eylea co-formulated with rinuccumab didn't meet its primary endpoint.
Chardan's Sell rating was predicated on risks surrounding the Praluent U.S. patent infringement case and Eylea's exposure to the theme of treatment burden reduction in wet AMD. Praluent, the anti-PCSK9 antibody, has a total market potential of $16.4 billion in 2020.
Eylea News Long-Term Negative
Eylea co-formulated with rinucumab didn't meet the primary endpoint of showing an improvement in best corrected visual acuity over Eylea monotherapy at 12 weeks in wet AMD. Chardan noted that the company plans to report additional data at a future medical conference. The firm believes the news is a long-term negative as Regeneron is exposed to what it expects could be a 2017 theme in wet AMD of treatment burden reduction.
Chardan said it repeatedly raised doubts over whether REGN2176-3 is flawed versus Ophthotech Corp's OPHT Fovista and REGN2176-3 approach is better than using Eylea alone.
Hanging By A Thread On Praluent
On Praluent, the firm believes if Amgen, Inc.'s AMGN patent on Repatha holds, then Sanofi SA (ADR) SNY/Regeneron would have to cough up 10-20 percent as royalties, or roughly $750 million of operating income per year to Amgen. In the worst case, if Rengeneron has to completely give up on Praluent, the firm sees a $2 billion EBIT transfer.
Accordingly, the firm believes The Medicines Company MDCO/Alnylam Pharmaceuticals, Inc. ALNY have preferable profiles for investors seeking to access PCSK9 inhibitor market dynamics, due to the RNAi approach.
The firm's $325 price target on Regeneron is based on a probability-adjusted modeling of key franchises.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.